Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 08:00 ET | Source: Immutep Limited

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting...
November 29, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
August 12, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
May 17, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
March 05, 2021 08:00 ET | Source: Immutep Limited

Immutep Expands Part B of TACTI-002 Study

Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
December 29, 2020 16:54 ET | Source: Immutep Limited

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
November 09, 2020 16:10 ET | Source: Immutep Limited

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
November 09, 2020 08:00 ET | Source: Immutep Limited

Immutep Announces Australian Patent Grant For IMP701 Antibody

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules...
May 01, 2017 08:30 ET | Source: TESARO, Inc.

TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...